Perils and Problems in Bispecific T-Cell Engager Antibodies
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Bispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity. CRS, characterized by cytokine release, is the most common, potentially life-threatening toxicity. Neurotoxicity presents as neurological symptoms and on-target, off-tumour toxicity damages healthy cells. Incidence and severity vary based on BsAb type, dose, patient factors, and tumor characteristics. For this study, articles pertaining to BsAb toxicity were searched on PubMed. Moreover, the management involves early recognition, dose modification, supportive care, and, in severe cases, immunosuppressive therapy or treatment discontinuation. Clinicians must carefully assess risks and benefits, considering individual patient profiles. Close monitoring and multidisciplinary collaboration are crucial for effective BsAb therapy. All in all, while toxicity is a concern, with vigilant management, BsAbs remain a valuable cancer treatment option.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current drug safety - (2024) vom: 27. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khushboo, Bisht [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bispecific antibodies |
|---|
| Anmerkungen: |
Date Revised 29.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0115748863286774240219094217 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369143221 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369143221 | ||
| 003 | DE-627 | ||
| 005 | 20240301233305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0115748863286774240219094217 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM369143221 | ||
| 035 | |a (NLM)38424423 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khushboo, Bisht |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Perils and Problems in Bispecific T-Cell Engager Antibodies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Bispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity. CRS, characterized by cytokine release, is the most common, potentially life-threatening toxicity. Neurotoxicity presents as neurological symptoms and on-target, off-tumour toxicity damages healthy cells. Incidence and severity vary based on BsAb type, dose, patient factors, and tumor characteristics. For this study, articles pertaining to BsAb toxicity were searched on PubMed. Moreover, the management involves early recognition, dose modification, supportive care, and, in severe cases, immunosuppressive therapy or treatment discontinuation. Clinicians must carefully assess risks and benefits, considering individual patient profiles. Close monitoring and multidisciplinary collaboration are crucial for effective BsAb therapy. All in all, while toxicity is a concern, with vigilant management, BsAbs remain a valuable cancer treatment option | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BsAbs. | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a bispecific antibodies | |
| 650 | 4 | |a cytokine release syndrome | |
| 650 | 4 | |a neurotoxic | |
| 650 | 4 | |a toxicity | |
| 700 | 1 | |a Kumar, Joshi Rajat |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug safety |d 2006 |g (2024) vom: 27. Feb. |w (DE-627)NLM181475790 |x 2212-3911 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:27 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0115748863286774240219094217 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 27 |c 02 | ||